The stock may react negatively to declining revenue and continued losses, but the recent capital raise and regulatory progress could support sentiment. Traders should monitor for signs of near-term commercialization, especially in the Rice program, and any updates on strategic alternatives. The path to profitability remains distant, making this a high-risk, long-term speculative play.
Price Chart
Executive Summary
Cibus reported Q4 2025 financial results with declining revenue and a wider net loss, driven by a $9.1 million non-cash impairment charge. Despite cost reductions in R&D and SG&A, the company continues to burn cash, with only $9.9 million in cash at year-end. However, it raised $22.3 million in January 2026 and highlighted progress in its Rice and Sustainable Ingredients programs, along with favorable global regulatory developments in gene editing. The stock remains speculative as commercial revenues remain near-term targets.
Key Financial Metrics
Key Facts
- Q4 2025 revenue declined to $1.06M from $1.21M in Q4 2024 (YoY decrease of 12.7%)
- Net loss widened to $31.9M in Q4 2025 vs. $25.8M in Q4 2024
- Reported $9.1M long-lived asset impairment related to the wind-down of its Roseville, MN facility
- R&D and SG&A expenses decreased by $3.0M and $1.7M YoY, respectively, due to cost-cutting
- Cash and cash equivalents were $9.9M as of December 31, 2025, but increased to ~$30M post-January 2026 offering
- Company expects cash runway into late Q3 2026 based on current burn rate and cost initiatives
- No commercial royalties yet; first customer payment in Sustainable Ingredients program received in Q4 2025
- EU political agreement on New Genomic Techniques and UK Precision Breeding Act represent key regulatory tailwinds
Financial Impact
Revenue down 12.7% YoY, net loss increased by $6.1M despite lower operating expenses due to asset impairment
Risk Factors
- Continued negative cash flow and reliance on future financings
- No significant revenue generation to date despite years of development
- Execution risk in transitioning from R&D to commercial licensing
- Regulatory momentum does not guarantee near-term monetization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257645 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $1.55 $1.38 | ▼ −10.97% | ▼ −11.68% | $1.38 (−10.97%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.25 $1.90 | ▲ +52.00% | ▲ +50.11% | $1.38 (+10.40%) |
Jun 9, 2026 20w ago | 8-K | $1.23 $1.50 | ▲ +21.95% | ▲ +20.50% | $1.38 (+12.20%) |
Jun 8, 2026 20w ago | Press Release | $1.23 $1.50 | ▲ +21.95% | ▲ +20.50% | $1.38 (+12.20%) |
May 26, 2026 22w ago | EFFECT | $1.43 $1.38 | ▲ +3.50% | ▲ +1.55% | $1.38 (+3.50%) |
May 14, 2026 23w ago | 8-K | $1.31 $1.27 | ▼ −3.05% | ▼ −5.17% | $1.38 (+5.34%) |
May 4, 2026 25w ago | Press Release | $1.49 $1.47 | ▼ −1.34% | ▼ −6.99% | $1.38 (−7.38%) |
Apr 20, 2026 27w ago | DEFA14A | $1.49 $1.28 | ▼ −14.09% | ▼ −19.01% | $1.38 (−7.38%) |
Mar 26, 2026 30w ago | 424B5 | $1.88 $1.49 | ▲ +20.74% | ▲ +33.49% | $1.38 (+26.60%) |
Mar 26, 2026 30w ago | Press Release | $2.13 $1.50 | ▼ −29.58% | ▼ −40.24% | $1.38 (−35.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers